"Novo Nordisk continues to advance solutions for patients that improve affordability and access to our medicines, whether they have insurance or not. Today, over 55 million people in the U.S. have coverage specifically for weight management medicines, and 90% of Wegovy® patients with coverage pay $0 to $25 a month for Wegovy®," said Dave Moore, Executive Vice President, U.S. Operations and Global Business Development and President of Novo Nordisk Inc. "With NovoCare® Pharmacy, patients and prescribers alike have another option that provides convenient access to all doses of real, FDA-approved Wegovy® at a reduced cost in our high-quality pen."

NovoCare® Pharmacy provides cash-paying patients who have been prescribed Wegovy® with the ability to schedule shipments of their Wegovy® prescriptions directly to their home. These home shipments are fulfilled by CenterWell Pharmacy, a six-time Specialty Pharmacy Patient Choice award winner for best-in-class customer satisfaction and commitment to patient care. Beyond convenient home delivery, NovoCare® also supports patients with benefit verification, refill reminders, and access to live support from a NovoCare® case manager. More information about NovoCare® Pharmacy is available at NovoCare.com

Additionally, NovoCare® Pharmacy offers patients access to authentic, FDA-approved Wegovy®, helping to avoid the significant risks that can be posed by the compounding marketplace, as warned by respected organizations, experts in the medical community, and the FDA. With an FDA-approved medicine like Wegovy®, healthcare professionals and patients can have clarity and confidence in knowing the medicine they are using has undergone rigorous review for safety, effectiveness, and quality. In the near future, the overall savings offer for Wegovy® will be updated so that cash-paying patients who use traditional retail pharmacies will also benefit from this lower price.